Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14656560903302265 | DOI Listing |
Publication Analysis
Top Keywords
vildagliptin clinical
4
clinical practice
4
practice review
4
review literature
4
literature vildagliptin
4
vildagliptin second
4
second member
4
member dpp-iv
4
dpp-iv inhibitor
4
inhibitor class
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!